Partner David Rosen was featured in a Clinical Leader Q&A, “Clinical Trial Deaths — Will Clearer Informed Consent Documents Be Enough?” about issues related to clinical trial consent documents, particularly as they relate to the lawsuit filed against the FDA by the Center for Responsible Science, clinical trial participants and the father of a deceased trial participant.
Rosen answered questions about whether or not the lawsuit will be successful, whether or not the current death rate from clinical trial treatments is concerning and what steps clinical trial stakeholders need to take to improve the informed consent process and make trials safer for patients.
Rosen answered questions about whether or not the lawsuit will be successful, whether or not the current death rate from clinical trial treatments is concerning and what steps clinical trial stakeholders need to take to improve the informed consent process and make trials safer for patients.
People
Related News
August 8, 2025
In the News
Gregory Husisian and David Simon Uncover the High Stakes of Tariff Evasion
Foley & Lardner LLP partners Gregory Husisian and David Simon are featured for their insights on how the U.S. government is cracking down on tariff evaders in the Newsweek article, "America Is Making Billions From Catching 'Tariff Cheaters.'"
August 7, 2025
In the News
Kyle Faget Weighs in on Trump Pharma Tariffs
Foley & Lardner LLP partner Kyle Faget assessed the Trump administration's implementation of import tariffs on the pharmaceutical industry in the Pharma Life Sciences article, "Trump's pharma import tariffs threaten drug pricing, generics."
August 5, 2025
In the News
Aaron Maguregui on Health Data Sharing Plan – 'I would expect the FTC to be heavily involved'
Foley & Lardner LLP partner Aaron Maguregui addressed a new health care data sharing initiative announced by the federal government in the Bloomberg Law article, "Digital Data-Sharing Plan Tests Limits of Health Privacy Rules."